Skip to main content
Premium Trial:

Request an Annual Quote

Roche Owns 57 Percent of Foundation Medicine Common Stock Following Tender Offer

NEW YORK (GenomeWeb) – Roche today announced the final results of its tender offer to purchase up to 15.6 million shares of common stock of Foundation Medicine at $50 per share, after disclosing preliminary results last week.

Foundation Medicine shareholders tendered a total of nearly 18.8 million shares of common stock. Because the offer was oversubscribed, Roche will accept 83.2 percent of shares offered by each tendering stockholder for purchase.

Roche now owns about 21 million shares of Foundation Medicine, including shares it already owned before the tender offer and 5 million newly issued shares it purchased for $50 per share last week. In total, these represent approximately 57 percent of Foundation's outstanding common stock on a fully diluted basis as of April 7.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more